Palivizumab in preemies reduces wheezing, study finds

05/8/2013 | DoctorsLounge.com

Premature babies who were given monoclonal antibody palivizumab to protect against respiratory syncytial virus infection had 61% fewer days of wheezing in the first year of life than the placebo group, Dutch researchers found. They also noted a lower number of infants with recurrent wheeze in the palivizumab group. The study was published in the New England Journal of Medicine.

View Full Article in:

DoctorsLounge.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA